Clinical Trial

Bio-CAR-T BS Study

Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this Study is the evaluation of post-infusion CAR-T (Chimeric Antigen Receptor T Cell) expansion and persistence in patients with DLBCL, PMBCL and ALL undergoing CAR-T therapy; and the feasibility and efficacy of the treatment in the real life practice.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-05-05; most recent amendment 2026-04-27.
Trial Details
NCT Number NCT05366569
Lead Sponsor Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Conditions Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Acute Lymphoblastic Leukemia (ALL)
Enrollment 45 participants
Start Date 2022-04-26
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-30